| 李 群,刘成霞,王明辉,董倩倩,范飞飞.双歧杆菌三联活菌胶囊与血必净注射液联合治疗术后早期炎性肠梗阻的疗效及对肠黏膜功能的影响[J].现代生物医学进展英文版,2021,(5):982-986. |
| 双歧杆菌三联活菌胶囊与血必净注射液联合治疗术后早期炎性肠梗阻的疗效及对肠黏膜功能的影响 |
| Effect of Bifidobacterium Triple Living Bacteria Capsule and Xuebijing Injection on Early Postoperative Inflammatory Small Bowel Obstruction and Its Effect on Intestinal Mucosa Function Inflammation |
| Received:August 28, 2020 Revised:September 23, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.05.039 |
| 中文关键词: 双歧杆菌三联活菌胶囊 血必净注射液 术后早期炎性肠梗阻 疗效 肠黏膜功能 肠壁黏膜炎症 |
| 英文关键词: Bifidobacterium Triple living bacteria capsule Xuebijing injection EPISBO Curative effect Intestinal mucosal function Intestinal mucosa inflammation |
| 基金项目: |
|
| Hits: 758 |
| Download times: 430 |
| 中文摘要: |
| 摘要 目的：研究双歧杆菌三联活菌胶囊与血必净注射液联合治疗术后早期炎性肠梗阻（EPISBO）的疗效及对肠黏膜功能和肠壁黏膜炎症的影响。方法：选择从2018年10月到2020年8月在医院接受治疗的EPISBO患者100例作为观察对象，按随机数表法将其分成观察组及对照组各50例，两组均常规治疗，对照组另给予血必净注射液，观察组在对照组的用药基础上再增用双歧杆菌三联活菌胶囊。两组均治疗7d，对比两组疗效，胃肠功能相关指标，肠黏膜功能相关指标，肠壁黏膜炎症指标，以及不良反应。结果：观察组的总有效率为98.00%，明显高于对照组的84.00%（均P＜0.05）。观察组的胃肠功能相关指标均分别明显优于对照组（均P＜0.05）。治疗7d后，两组的丙二醛（MDA）、二胺氧化酶（DAO）及乳酸（D-Lac）水平均明显低于治疗前，且观察组又低于对照组（P＜0.05）。两组的超氧化物歧化酶（SOD）水平明显高于治疗前，且观察组又高于对照组（P＜0.05）。治疗7d后两组的内毒素（LPS）、C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）及IL-1β水平均明显低于治疗前，且观察组又低于对照组（P＜0.05）。两组的不良反应相比，差异不显著（P＞0.05）。结论：应用双歧杆菌三联活菌胶囊联合血必净注射液治疗EPISBO的疗效和安全性均较好，且对肠黏膜功能和肠壁黏膜炎症具有较好的改善作用，值得推广。 |
| 英文摘要: |
| ABSTRACT Objective: To study the efficacy of Bifidobacterium Triple living bacteria capsule and Xuebijing injection on early postoperative inflammatory small bowel obstruction (EPISBO) and its effect on intestinal mucosa function and intestinal mucosa inflammation. Methods: From October 2018 to August 2020, 100 patients enrolled in Rongxian People's Hospital with EPISBO were randomly divided into observation group (n = 50) and control group (n = 50) by random digitial table method. The two groups were given conventional therapy, the control group was given Xuebijing injection, and the observation group was added bifidobacterium triple living bacteria capsule on the basis of the medicine used in the control group. The therapeutic effect, gastrointestinal function related index,intestinal mucosa function related index, intestinal mucosa inflammation related index and adverse reactions was compared between the two groups. Results: The total effective rate of the observation group was 98.00%, which was significantly higher than that of the control group of 84.00%(all P<0.05). The gastrointestinal function related index in the observation group was significantly better than those in the control group (P<0.05). After 7 days treatment, the levels of malondialdehyde (MDA), diamine oxidase (DAO) and lactic acid (D-Lac) in the two groups was significantly lower than those before treatment, and the level in the observation group was lower than that in the control group (P<0.05). The level of superoxide dismutase (SOD) in the two groups was significantly higher than that before treatment, and the level in the observation group was higher than that in the control group (P<0.05). The levels of endotoxin (LPS), C reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-1 β in the two groups was significantly lower than those before treatment 7 days after treatment. And the observation group was lower than the control group (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion: Bifidobacterium triple living bacteria capsule combined with Xuebijing injection is effective and safe in the treatment of EPISBO, and it can improve the function of intestinal mucosa and inflammation of intestinal mucosa, so it is worth popularizing. |
|
View Full Text
View/Add Comment Download reader |
| Close |
